2-氨基-9-(beta-d-2-脱氧核糖)嘌呤 | 3616-24-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 2-氨基-9-(beta-d-2-脱氧核糖)嘌呤
• 英文名称: 5-(2-Aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
• CAS: 3616-24-8
• 化学式: C₁₀H₁₃N₅O₃
• 分子量: 251.24
• InChiKey: KGCFUCMAUQBXMT-UHFFFAOYSA-N

物化性质

• 沸点：
  661.8±65.0 °C(Predicted)
• 密度：
  1.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

安全信息

• 海关编码：
  2934999090

文献信息

• Modulators of DUX4 for regulation of muscle function
  申请人：GENEA BIOCELLS USA (HOLDINGS), INC.

  公开号：US10933068B2

  公开（公告）日：2021-03-02

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.

  本文公开了治疗面肱骨肌营养不良症和其他肌肉疾病或紊乱的方法和组合物。在某些情况下，这些方法和组合物涉及使用甲基转移酶抑制剂来抑制或抑制肌肉细胞中 DUX4 的表达。本文进一步公开了用于筛选治疗面阔肌营养不良症和其他肌肉疾病的化合物的方法和基于细胞的检测方法。
• Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
  申请人：Renzi Paolo

  公开号：US20050032723A1

  公开（公告）日：2005-02-10

  The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.

  本发明涉及核苷酸替代物在提高核酸分子体内效力以及抑制哺乳动物炎症方面的用途。更具体地说，本发明涉及 2′6′二氨基嘌呤（DAP）及其类似物本身在抗炎组合物中的用途，还涉及制备与传统寡核苷酸相比具有更高的体内生理效率和更低的毒性的核酸分子。本发明特别适用于制备治疗肺/呼吸道疾病的反义寡核苷酸，如囊性纤维化、哮喘、慢性支气管炎、慢性阻塞性肺病、嗜酸性支气管炎、过敏、过敏性鼻炎、肺纤维化、成人呼吸窘迫综合征、鼻窦炎、呼吸道合胞病毒或其他病毒性呼吸道感染和癌症。
• METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
  申请人：Topigen Pharmaceuticals Inc.

  公开号：EP1406667B1

  公开（公告）日：2008-02-20
• METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
  申请人：Topigen Pharmaceutiques Inc

  公开号：EP1406667A2

  公开（公告）日：2004-04-14
• METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
  申请人：RENZI Paolo

  公开号：US20100286235A1

  公开（公告）日：2010-11-11

  The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′ diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.